Reckitt Promises ‘Big’ Q4 As Consumer Health Market Share Rebounds

A better than expected showing from its Health business in its latest quarter has teed up Reckitt for a big finish to the year.

ReckittBenckiser
• Source: reckitt/shutterstock

Reckitt is “planning for a big Q4,” CEO Kris Licht told analysts after the UK-based firm delivered better than expected results at its Health division in the latest quarter.

In Q3, like-for-like Health sales advanced by 3.2% – ahead of consensus at 2.6% – driven by market share gains for key consumer health brands. “I feel very good about the momentum in our Health business,” Licht told Reckitt’s earnings call on 23 October

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

Recordati Relying On OTC To Act As ‘Booster’ To Growth

 
• By 

In categories like cough & cold and gastrointestinal, OTC products have a pivotal role to play in helping Recordati hit its sales targets for the 2025-2027 period.

Bayer Consumer Health Delivers ‘Balanced’ Q1

 
• By 

With sales gains across most of its regions and product categories, Bayer Consumer Health got off to a good start to the year.

Mitigating Tariff Impacts, Kenvue Adjusts Outlook

 

“The situation has evolved considerably” since Kenvue gave its initial full-year outlook in February, “and remains quite fluid,” says president and CEO Thibaut Mongon as firm reports Q1 net sales decreasing 3.9% to $3.7bn

Looming Tariffs Give Boost To Latest PCH Results While Cutting Costs In Response Takes Priority

 

Looming imposition of tariffs by Trump on imports from most every country had an influence on consumers during the January-March period, particularly on online shopping. Increasing product prices on the table, “but our efforts are going to start with cost savings,” says CFO Christine Sacco.

More from Wellness

Time’s Up For Time-Line Mitopure Supplement Marketer’s Aging Claims In NAD Review

 

NAD says Amazentis didn’t substantiate cellular performance and muscle function claims for its supplements containing proprietary ingredient Mitropure but provided “a sufficiently reliable and reasonable basis” for “clinically proven to revitalize mitochondria.”

Kennedy’s Balancing Act: Push MAHA, Trim Regs

 

Same-day announcements of RFIs from HHS secretary cover nutrient review process for infant formula and Kennedy’s “10-to-1 deregulatory policy” as part of president’s “broader federal effort to reduce regulatory burdens and increase transparency.”

Haleon Utilizing AI To Develop Natural CHC Products

 
• By 

Haleon is partnering with San Francisco's Brightseed to utilize its AI technology to identify bioactive compounds in plants for use in consumer health products.